Briefly Bio, a techbio startup, has launched with $1.2 million in pre-seed funding to address the reproducibility crisis in science. The company’s software uses AI to convert experiment descriptions into a consistent format, automatically filling gaps and spotting errors. This approach aims to make lab work more reproducible by helping scientists capture and share their work clearly and consistently, potentially saving the industry billions spent on failed experiment reproductions annually.
Founded by Dr. Katya Putintseva, Harry Rickerby, and Staffan Piledahl, Briefly Bio creates a shared language for experiments that is consistent across scientists and clear for collaborators to understand. The funding round was led by Compound VC, with participation from NP Hard, Tiny VC, and angel investors from tech and biotech sectors. The startup’s goal is to enable scientists to build upon each other’s work more efficiently, similar to how GitHub has facilitated collaboration among software engineers.
The startup’s solution comes at a crucial time when AI and high-throughput experimentation are poised to significantly improve scientific discovery efficiency. Briefly Bio’s infrastructure aims to provide the necessary consistency and transparency in dataset generation, which is critical for realizing the potential of these advancements. The company has already garnered positive feedback from scientists and industry professionals who praise its ability to save time, improve knowledge sharing, and enhance lab management.
Briefly Bio’s vision is to create a future where scientists can avoid “reinventing the wheel” by spending time and resources on experiments they can’t reproduce. By enabling more efficient collaboration and data sharing, the company aims to accelerate scientific discovery in biology. This approach is expected to produce datasets that will rapidly expand our understanding of biological systems and processes.
